Epidemiology and treatment of post-stroke depression

Stefano Paolucci, Stefano Paolucci

Abstract

Mood depression is a common and serious complication after stroke. According to epidemiological studies, nearly 30% of stroke patients develop depression, either in the early or in the late stages after stroke. Although depression may affect functional recovery and quality of life after stroke, such condition is often ignored. In fact, only a minority of patients is diagnosed and even fewer are treated in the common clinical practice. Moreover, the real benefits of antidepressant (AD) therapy in post-stroke depression have not been fully clarified. In fact, controlled studies on the effectiveness of ADs in post stroke depression (PSD) are relatively few. Today, data available suggest that ADs may be generally effective in improving mood, but guidelines for the optimal treatment and its length are still lacking.

Keywords: antidepressant; depression; stroke.

References

    1. Aben I, Verhey F, Strik J, et al. A comparative study into the one year cumulative incidence of depression after stroke and myocardial infarction. J Neurol Neurosurg Psychiatry. 2003;74:581–5.
    1. Alexopoulos GS. “The depression-executive dysfunction syndrome of late life”: a specific target for D3 agonists? Am J Geriatr Psychiatry. 2001;9:22–9.
    1. Alexopoulos GS. The vascular depression hypothesis: 10 years later. Biol Psychiatry. 2006;60:1304–5.
    1. Alexopoulos GS, Meyers BS, Young RC, et al. ‘Vascular depression’ hypothesis. Arch Gen Psychiatry. 1997a;54:915–22.
    1. Alexopoulos GS, Meyers BS, Young RC, et al. Clinically defined vascular depression. Am J Psychiatry. 1997b;154:562–5.
    1. Almeida OP, Waterreus A, Hankey GJ. Preventing depression after stroke: Results from a randomized placebo-controlled trial. J Clin Psychiatry. 2006;67:1104–9.
    1. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke. 1994a;25:1099–104.
    1. Andersen G, Vestergaard K, Riis J, et al. Incidence of post-stroke depression during the first year in a large unselected stroke population determined using a valid standardized rating scale. Acta Psychiatr Scand. 1994b;90:190–5.
    1. Anderson C, Hackett M, House A. Interventions for preventing depression after stroke. Cochrane Database Syst Rev. 2004;2:CD003689.
    1. Bak S, Tsiropoulos I, Kjaersgaard JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke. 2002;33:1465–73.
    1. Bakish D. New standard of depression treatment: remission and full recovery. J Clin Psychiatry. 2001;62(Suppl 26):5–9.
    1. Berg A, Palomaki H, Lehtihalmes M, et al. Poststroke depression in acute phase after stroke. Cerebrovasc Dis. 2001;12:14–20.
    1. Bhogal SK, Teasell R, Foley N, et al. Heterocyclics and selective serotonin reuptake inhibitors in the treatment and prevention of poststroke depression. J Am Geriatr Soc. 2005;53:1051–7.
    1. Brodaty H, Withall A, Altendorf A, et al. Rates of depression at 3 and 15 months poststroke and their relationship with cognitive decline: the Sydney Stroke Study. Am J Geriatr Psychiatry. 2007;15:477–86.
    1. Carson AJ, MacHale S, Allen K, et al. Depression after stroke and lesion location: a systematic review. Lancet. 2000;356:122–6.
    1. Chemerinski E, Robinson RG, Kosier JT. Improved recovery in activities of daily living associated with remission of poststroke depression. Stroke. 2001;32:113–17.
    1. Chen Y, Guo JJ. Meta-analysis of antidepressant treatment for patients with poststroke depression. Stroke. 2006;37:1365–6.
    1. Chen Y, Patel NC, Guo JJ, et al. Antidepressant prophylaxis for poststroke depression: a meta-analysis. Int Clin Psychopharmacol. 2007;22:159–66.
    1. Choi-Kwon S, Han SW, Kwon SU, et al. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke. 2006;37:156–61.
    1. Dahmen N, Marx J, Hopf HC, et al. Therapy of early poststroke depression with venlafaxine: safety, tolerability, and efficacy as determined in an open, uncontrolled clinical trial. Stroke. 1999;30:691–2.
    1. Dam M, Tonin P, De Boni A, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke. 1996;27:1211–14.
    1. Damecour CL, Caplan D. The relationship of depression to symptomatology and lesion site in aphasic patients. Cortex. 1991;27:385–401.
    1. de Abajo FJ, Jick H, Derby L, et al. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. Br J Clin Pharmacol. 2000;50:43–7.
    1. Fedoroff JP, Robinson RG. Tricyclic antidepressants in the treatment of poststroke depression. J Clin Psychiatry. 1989;50(Suppl):18–23.
    1. Fedoroff JP, Starkstein SE, Parikh RM, et al. Are depressive symptoms nonspecific in patients with acute stroke? Am J Psychiatry. 1991;148:1172–6.
    1. Fruehwald S, Gatterbauer E, Rehak P, et al. Early fluoxetine treatment of post-stroke depression A three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol. 2003;250:347–51.
    1. Gainotti G, Antonucci G, Marra C, et al. Relation between depression after stroke, antidepressant therapy, and functional recovery. J Neurol Neurosurg Psychiatry. 2001;71:258–61.
    1. Gill D, Hatcher S. A systematic review of the treatment of depression with antidepressant drugs in patients who also have a physical illness. J Psychosom Res. 1999;47:131–43.
    1. Gillen R, Tennen H, McKee TE, et al. Depressive symptoms and history of depression predict rehabilitation efficiency in stroke patients. Arch Phys Med Rehabil. 2001;82:1645–9.
    1. Gonzalez-Torrecillas JL, Mendlewicz J, Lobo A. Effects of early treatment of poststroke depression on neuropsychological rehabilitation. Int Psychogeriatr. 1995;7:547–60.
    1. Gordon WA, Hibbard MR. Poststroke depression: an examination of the literature. Arch Phys Med Rehabil. 1997;78:658–63.
    1. Gustafson Y, Nilsson I, Mattsson M, et al. Epidemiology and treatment of post-stroke depression. Drugs Aging. 1995;7:298–309.
    1. Hackett ML, Anderson CS, House AO. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2004:CD003437.
    1. Hackett ML, Anderson CS, House AO. Management of depression after stroke: a systematic review of pharmacological therapies. Stroke. 2005a;36:1098–103.
    1. Hackett ML, Yapa C, Parag V, et al. Frequency of depression after stroke: a systematic review of observational studies. Stroke. 2005b;36:1330–40.
    1. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002;3:13–37.
    1. Herrmann N, Black SE, Lawrence J, et al. The Sunnybrook Stroke Study: a prospective study of depressive symptoms and functional outcome. Stroke. 1998;29:618–24.
    1. Hickie I, Scott E, Mitchell P, et al. Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biol Psychiatry. 1995;37:151–60.
    1. House A, Dennis M, Hawton K, et al. Methods of identifying mood disorders in stroke patients: experience in the Oxfordshire Community Stroke Project. Age Ageing. 1989;18:371–9.
    1. House A, Knapp P, Bamford J, et al. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke. 2001;32:696–701.
    1. Jorge RE, Robinson RG, Arndt S, et al. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry. 2003;160:1823–9.
    1. Jorgensen L, Engstad T, Jacobsen BK. Higher incidence of falls in long-term stroke survivors than in population controls: depressive symptoms predict falls after stroke. Stroke. 2002;33:542–7.
    1. Kauhanen M, Korpelainen JT, Hiltunen P, et al. Poststroke depression correlates with cognitive impairment and neurological deficits. Stroke. 1999;30:1875–80.
    1. Kauhanen ML, Korpelainen JT, Hiltunen P, et al. Aphasia, depression, and non-verbal cognitive impairment in ischaemic stroke. Cerebrovasc Dis. 2000;10:455–61.
    1. Kellermann M, Fekete I, Gesztelyi R, et al. Screening for depressive symptoms in the acute phase of stroke. Gen Hosp Psychiatry. 1999;21:116–21.
    1. Kim P, Warren S, Madill H, et al. Quality of life of stroke survivors. Qual Life Res. 1999;8:293–301.
    1. King RB. Quality of life after stroke. Stroke. 1996;27:1467–72.
    1. Kneebone II, Dunmore E. Psychological management of post-stroke depression. Br J Clin Psychol. 2000;39(Pt 1):53–65.
    1. Kotila M, Numminen H, Waltimo O, et al. Post-stroke depression and functional recovery in a population-based stroke register. The Finnstroke study. Eur J Neurol. 1999;6:309–12.
    1. Laska AC, Martensson B, Kahan T, et al. Recognition of Depression in Aphasic Stroke Patients. Cerebrovasc Dis. 2007;24:74–9.
    1. Lauritzen L, Bendsen BB, Vilmar T, et al. Post-stroke depression: combined treatment with imipramine or desipramine and mianserin. A controlled clinical study. Psychopharmacology (Berl) 1994;114:119–22.
    1. Lincoln NB, Flannaghan T. Cognitive behavioral psychotherapy for depression following stroke: a randomized controlled trial. Stroke. 2003;34:111–15.
    1. Lincoln NB, Flannaghan T, Sutcliffe L, et al. Evaluation of cognitive behavioural treatment for depression after stroke: a pilot study. Clin Rehabil. 1997;11:114–22.
    1. Linden T, Blomstrand C, Skoog I. Depressive disorders after 20 months in elderly stroke patients. A case-control study. Stroke. 2007;38:1860–3.
    1. Lipsey JR, Robinson RG. Nortriptyline for post-stroke depression. Lancet. 1984;1:803.
    1. Loubinoux I, Pariente J, Boulanouar K, et al. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: Double-blind, placebo-controlled, fMRI study in healthy subjects. Neuroimage. 2002;15:26–36.
    1. Mast BT, MacNeill SE, Lichtenberg PA. Post-stroke and clinically-defined vascular depression in geriatric rehabilitation patients. Am J Geriatr Psychiatry. 2004;12:84–92.
    1. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost. 2004;91:119–28.
    1. Miyai I, Reding MJ. Effects of antidepressants on functional recovery following stroke: a double-blind study. J Neuro Rehab. 1998;12:5–13.
    1. Morris PL, Robinson RG, Andrzejewski P, et al. Association of depression with 10-year poststroke mortality. Am J Psychiatry. 1993;150:124–9.
    1. Murray V, von Arbin M, Bartfai A, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry. 2005;66:708–16.
    1. Neau JP, Ingrand P, Mouille-Brachet C, et al. Functional recovery and social outcome after cerebral infarction in young adults. Cerebrovasc Dis. 1998;8:296–302.
    1. Paolucci S, Antonucci G, Grasso MG, et al. Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study. Cerebrovasc Dis. 2001;12:264–71.
    1. Paolucci S, Antonucci G, Pratesi L, et al. Poststroke depression and its role in rehabilitation of inpatients. Arch Phys Med Rehabil. 1999;80:985–90.
    1. Paolucci S, Gandolfo C, Provinciali L, et al. on behalf of DESTRO Study Group. The Italian multicenter observational study on post-stroke depression (DESTRO) J Neurol. 2006;253:556–62.
    1. Pariente J, Loubinoux I, Carel C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol. 2001;50:718–29.
    1. Pohjasvaara T, Vataja R, Leppavuori A, et al. Depression is an independent predictor of poor long-term functional outcome post-stroke. Eur J Neurol. 2001;8:315–19.
    1. Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry. 2004;65:1642–53.
    1. Ramasubbu R, Robinson RG, Flint AJ, et al. Functional impairment associated with acute poststroke depression: the Stroke Data Bank Study. J Neuropsychiatry Clin Neurosci. 1998;10:26–33.
    1. Rampello L, Chiechio S, Nicoletti G, et al. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology (Berl) 2004;173:73–8.
    1. Reding MJ, Orto LA, Winter SW, et al. Antidepressant therapy after stroke. A double-blind trial. Arch Neurol. 1986;43:763–5.
    1. Robinson RG, Schultz SK, Castillo C, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000;157:351–9.
    1. Sarti C, Rastenyte D, Cepaitis Z, et al. International trends in mortality from stroke, 1968 to 1994. Stroke. 2000;31:1588–601.
    1. Schubert DS, Taylor C, Lee S, et al. Detection of depression in the stroke patient. Psychosomatics. 1992;33:290–4.
    1. Schulz R, Beach SR, Ives DG, et al. Association between depression and mortality in older adults: the Cardiovascular Health Study. Arch Intern Med. 2000;160:1761–8.
    1. Schwartz JA, Speed NM, Brunberg JA, et al. Depression in stroke rehabilitation. Biol Psychiatry. 1993;33:694–9.
    1. Simpson S, Baldwin RC, Jackson A, et al. Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression. Psychol Med. 1998;28:1015–26.
    1. Sinyor D, Amato P, Kaloupek DG, et al. Post-stroke depression: relationships to functional impairment, coping strategies, and rehabilitation outcome. Stroke. 1986;17:1102–7.
    1. Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics. 1996;37:12–6.
    1. [SPREAD] Stroke Prevention and Educational Awareness Diffusion. Complicanze psico-cognitive dell’ictus. In Ictus cerebrale: linee guida italiane di prevenzione e trattamento. Milano: Pubblicazioni Catel – Hyperphar Group SpAp; 2005. pp. 435–79.
    1. Taylor WD, Steffens DC, Krishnan KR. Psychiatric disease in the twenty-first century: The case for subcortical ischemic depression. Biol Psychiatry. 2006;60:1299–303.
    1. Townend BS, Whyte S, Desborough T, et al. Longitudinal prevalence and determinants of early mood disorder post-stroke. J Clin Neurosci. 2007;14:429–34.
    1. Turner-Stokes L, Hassan N. Depression after stroke: a review of the evidence base to inform the development of an integrated care pathway. Part 2: Treatment alternatives. Clin Rehabil. 2002;16:248–60.
    1. van de Weg FB, Kuik DJ, Lankhorst GJ. Post-stroke depression and functional outcome: a cohort study investigating the influence of depression on functional recovery from stroke. Clin Rehabil. 1999;13:268–72.
    1. Van de MH, Geurts AC, Van Limbeek J. Pharmacologic treatment of poststroke depression: a systematic review of the literature. Top Stroke Rehabil. 2003;10:79–92.
    1. Vataja R, Leppavuori A, Pohjasvaara T, et al. Poststroke depression and lesion location revisited. J Neuropsychiatry Clin Neurosci. 2004;16:156–62.
    1. Verdelho A, Henon H, Lebert F, et al. Depressive symptoms after stroke and relationship with dementia: A three-year follow-up study. Neurology. 2004;62:905–11.
    1. Wiart L, Petit H, Joseph PA, et al. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke. 2000;31:1829–32.
    1. Williams LS, Ghose SS, Swindle RW. Depression and other mental health diagnoses increase mortality risk after ischemic stroke. Am J Psychiatry. 2004;161:1090–5.
    1. Windle V, Corbett D. Fluoxetine and recovery of motor function after focal ischemia in rats. Brain Res. 2005;1044:25–32.
    1. Yamakawa Y, Satoh S, Sawa S, et al. Efficacy of milnacipran on poststroke depression on inpatient rehabilitation. Psychiatry Clin Neurosci. 2005;59:705–10.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi